scholarly journals Serum levels of brain-derived neurotrophic factor (BNDF) in multiple sclerosis patients withTrichuris suisova therapy

Parasite ◽  
2013 ◽  
Vol 20 ◽  
pp. 55 ◽  
Author(s):  
Berit Rosche ◽  
Jonas Werner ◽  
Friderike Joëlle Benzel ◽  
Lutz Harms ◽  
Heidi Danker-Hopfe ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Neurotrophic Factor ◽  
Serum Levels ◽  
Brain Derived Neurotrophic Factor ◽  
Multiple Sclerosis Patients

scholarly journals Interleukin-10 and brain-derived neurotrophic factor responses to the Mat Pilates training in women with multiple sclerosis

2018 ◽  
Vol 28 (4) ◽  
pp. 31668
Author(s):  
Elham Eftekhari ◽  
Masoud Etemadifar
Keyword(s):  
Multiple Sclerosis ◽  
Neurotrophic Factor ◽  
Training Group ◽  
Serum Levels ◽  
Brain Derived Neurotrophic Factor ◽  
Interleukin 10 ◽  
Analysis Of Covariance ◽  
Control Group ◽  
P Value ◽  
Before And After

AIMS: To determine the effect of Mat Pilates on serum levels of interleukin-10 and brain-derived neurotrophic factor in women with multiple sclerosis.METHODS: Thirty women with multiple sclerosis with mild to moderate disability were recruited and randomly divided into equal Pilates training and Control groups. Patients in the training group accomplished a Pilates program three times a week for eight weeks. The Control group maintained their routine lifestyle. The serum level of interleukin-10 and brain-derived neurotrophic factor were measured before and after the protocol. The differences between groups were assessed by using analysis of covariance test to compare post-tests by considering covariate pre-tests (assuming a p-value <0.05 as significant).RESULTS: There were no significant changes in interleukin-10 (13.09±5.36 ng/ml in the Pilates training group compared to 13.21±4.76 ng/ml in the Control group, p= 0.81), whereas an increase in brain-derived neurotrophic factor was observed after eight-week Pilates training (11550.14±2619.60 ng/ml in the Pilates training group compared to 9664.35±3161.66 ng/ml in the Control group, p= 0.03).CONCLUSIONS: The results suggest that the intensity and duration of this protocol was not related to significant changes in interleukin-10, but was followed by an increase in brain-derived neurotrophic factor in these patients. Based on this finding, physical activity according to the individual’s ability is recommended for patients with multiple sclerosis, in parallel with drug therapy.

scholarly journals Preservation of gray matter volume in multiple sclerosis patients with the Met allele of the rs6265 (Val66Met) SNP of brain-derived neurotrophic factor

2007 ◽  
Vol 16 (22) ◽  
pp. 2659-2668 ◽  
Author(s):  
Robert Zivadinov ◽  
Bianca Weinstock-Guttman ◽  
Ralph Benedict ◽  
Miriam Tamaño-Blanco ◽  
Sara Hussein ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Gray Matter ◽  
Neurotrophic Factor ◽  
Gray Matter Volume ◽  
Brain Derived Neurotrophic Factor ◽  
Matter Volume ◽  
Multiple Sclerosis Patients

scholarly journals Altered production of brain-derived neurotrophic factor by peripheral blood immune cells in multiple sclerosis

2010 ◽  
Vol 16 (10) ◽  
pp. 1178-1188 ◽  
Author(s):  
Satoshi Yoshimura ◽  
Hirofumi Ochi ◽  
Noriko Isobe ◽  
Takuya Matsushita ◽  
Kyoko Motomura ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Peripheral Blood Mononuclear Cells ◽  
Neurotrophic Factor ◽  
Peripheral Blood ◽  
Interferon Beta ◽  
Mononuclear Cells ◽  
Brain Derived Neurotrophic Factor ◽  
Peripheral Blood Mononuclear ◽  
Factor Production ◽  
Multiple Sclerosis Patients

Background: Within multiple sclerosis lesions, brain-derived neurotrophic factor is detected in neurons and immunocytes. Objective: To clarify brain-derived neurotrophic factor production by peripheral blood immunocytes and its relationship with clinical parameters in multiple sclerosis. Methods: Serum brain-derived neurotrophic factor levels were measured by conventional enzyme-linked immunosorbent assay while brain-derived neurotrophic factor production by immunocytes was determined by an in situ enzyme-linked immunosorbent assay in 74 multiple sclerosis patients, 32 healthy controls, and 86 patients with other neurological diseases. The tyrosine kinase receptor TrkB expression level in peripheral blood mononuclear cells was measured by real-time polymerase chain reaction. Results: Multiple sclerosis patients showed significantly higher serum brain-derived neurotrophic factor levels than healthy controls and patients with other neurological diseases. Multiple sclerosis patients with high brain-derived neurotrophic factor levels were younger, and showed fewer relapse numbers than those with low brain-derived neurotrophic factor levels. Brain-derived neurotrophic factor production by T cells increased with age in healthy controls, but not in multiple sclerosis patients. Interferon beta induced a significant increase in serum brain-derived neurotrophic factor levels. Brain-derived neurotrophic factor production from T cells and TrkB expression levels in peripheral blood mononuclear cells were significantly enhanced in interferon beta-treated multiple sclerosis patients compared with untreated ones. Conclusions: A high brain-derived neurotrophic factor level is related to early mild disease in young multiple sclerosis patients. Interferon beta potentiates brain-derived neurotrophic factor production and brain-derived neurotrophic factor receptor expression in peripheral blood mononuclear cells, which may act beneficially.

Increased Serum Brain-derived Neurotrophic Factor in Multiple Sclerosis Patients on Interferon-β and Its Impact on Functional Abilities

2015 ◽  
Vol 20 (4) ◽  
pp. 57-60 ◽  
Author(s):  
Masoud Mehrpour ◽  
Fahimeh H. Akhoundi ◽  
Maryam Delgosha ◽  
Hosein Keyvani ◽  
Mohammad R. Motamed ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Neurotrophic Factor ◽  
Brain Derived Neurotrophic Factor ◽  
Functional Abilities ◽  
Interferon Β ◽  
Multiple Sclerosis Patients

Brain-derived neurotrophic factor is associated with coronary macrophage infiltrates in patients with acute coronary syndrome

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
R.A Montone ◽  
M Camilli ◽  
M Russo ◽  
M Del Buono ◽  
F Gurguglione ◽  
...  
Keyword(s):  
Acute Coronary Syndrome ◽  
Neurotrophic Factor ◽  
Serum Levels ◽  
Brain Derived Neurotrophic Factor ◽  
C Reactive Protein ◽  
St Segment Elevation ◽  
Protein Levels ◽  
Reactive Protein ◽  
Coronary Syndrome ◽  
St Segment

Abstract Background Brain-derived neurotrophic factor (BDNF) is a neurotrophine that plays a key role in the regulation of both central and peripheral nervous system. Moreover, BDNF is secreted in multiple tissues and exerts systemic, autocrine, and paracrine effects in the cardiovascular system. Of importance, BDNF expression was enhanced in macrophages and smooth muscle cells in atherosclerotic coronary arteries and may be involved in thrombus formation. Thus, BDNF has been suggested as an important link between inflammation and thrombosis, potentially involved in the pathogenesis of acute coronary syndrome (ACS). Purpose In our study we aimed at assessing serum levels of BDNF in patients with ACS, evaluating differences according to clinical presentation [ST-segment elevation myocardial infarction (STEMI) vs. Non-ST-segment elevation ACS (NSTE-ACS)]. Moreover, we assessed the presence of optical coherence (OCT)-defined macrophage infiltrates (MØI) in the culprit vessel of ACS patients and evaluated their relationship with BDNF levels. Methods ACS patients were prospectively selected. Blood samples were collected at admission and serum levels of BDNF were subsequently assessed. Presence of OCT-defined MØI along the culprit vessel was assessed. Results 166 ACS patients were enrolled [mean age 65.3±11.9 years, 125 (75.3%) male, 109 STEMI, 57 NSTE-ACS]. Serum levels of BDNF were higher among STEMI patients compared with NSTE-ACS [median (IQR) 2.48 pg/mL (1.54–3.34) vs. 2.12 pg/mL (1.34–2.47), p=0.007], while C-reactive protein levels did not differ between the two groups. OCT assessment was performed in 53 patients and MØI were detected in 27 patients. Of importance, patients with MØI in the culprit vessel had higher levels of BDNF compared with patients without MØI [median (IQR) 2.23 pg/mL (1.38–2.53) vs. 1.41 pg/mL (0.93–2.07), p=0.023], while C-reactive protein levels did not differ between the two groups. Of note, at multivariate regression analysis BDNF levels were independent predictor of MØI [OR: 2.20; 95% CI (1.02–4.74), p=0.043]. Conclusions Serum levels of BDNF may reliable identify the presence of local macrophage inflammatory infiltrates in patients with ACS. Moreover, BDNF levels are higher in patients with STEMI compared with NSTE-ACS. Taken together, these data suggest that BDNF may represent an interesting link between local inflammatory activation and enhanced thrombosis in ACS. BDNF serum levels Funding Acknowledgement Type of funding source: None

scholarly journals Comparison of Antioxidant Status and Vitamin D Levels between Multiple Sclerosis Patients and Healthy Matched Subjects

2014 ◽  
Vol 2014 ◽  
pp. 1-5 ◽  
Author(s):  
Ehsan Hejazi ◽  
Reza Amani ◽  
Naser SharafodinZadeh ◽  
Bahman Cheraghian
Keyword(s):  
Multiple Sclerosis ◽  
Vitamin D ◽  
Dietary Intake ◽  
Antioxidant Status ◽  
Sun Exposure ◽  
Total Antioxidant Status ◽  
Serum Levels ◽  
Study Groups ◽  
Vitamin D Levels ◽  
Multiple Sclerosis Patients

Objective. The aim of the present study was to compare the serum levels of total antioxidant status (TAS) and 25(OH) D3 and dietary intake of multiple sclerosis (MS) patients with those of normal subjects.Method. Thirty-seven MS patients (31 women) and the same number of healthy matched controls were compared for their serum levels and dietary intake of 25(OH) D3 and TAS. Sun exposure and the intake of antioxidants and vitamin D rich foods were estimated through face-to-face interview and food frequency questionnaire.Results. Dietary intake of antioxidants and vitamin D rich foods, vitamin C, vitamin A, and folate was not significantly different between the two groups. There were also no significant differences in the mean levels of 25(OH) D3 and TAS between the study groups. Both groups had low serum levels of 25(OH) D3 and total antioxidants.Conclusion. No significant differences were detected in serum levels and dietary intake of vitamin D and antioxidants between MS patients and healthy controls. All subjects had low antioxidant status and vitamin D levels.

Sign in / Sign up

Export Citation Format

Share Document